Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03305562 · ClinicalTrials.gov registry record
Pediatric Hypertension Registry (PHREG)
A clinical trial, sponsored by Wake Forest University Health Sciences.
- Terminated
- Registry status
- 179
- Enrollment target
NCT03305562: Clinical Trial study, sponsored by Wake Forest University Health Sciences.
NCT03305562 is a clinical trial that was terminated before completion, run by Wake Forest University Health Sciences. The registered enrollment target is 179 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03305562 was terminated before completion, sponsored by Wake Forest University Health Sciences.
- TERMINATED
- Registry status
- 179 participants
- Enrollment target
Study Summary
Pediatric hypertension is increasingly common and is a precursor for adult cardiovascular and renal disease. But even during childhood, hypertension is associated with significant morbidity, including cognitive impairment and organ damage. However, the cause of pediatric hypertension, the response to treatment, and the mechanisms behind organ damage are incompletely understood. Due to these limitations, there are no first-line medications, and treatment is often inadequate. An improved comprehension of the course of pediatric hypertension could enhance clinical care. The goal of this proposal is to create a registry of patients with hypertension to better enable research into this important disease. This patient registry will enhance the investigators ability to quickly collect and analyze data for research studies.
Primary Outcome
Auscultated blood pressure measurements in clinic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 179 participants |
| Start Date | 2017-09-20 |
| Est. Completion | 2021-06-22 |
Why NCT03305562 stopped before completion
NCT03305562 is an observational study that tracks outcomes without assigning an intervention. The registered 179 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03305562 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03305562 about?
NCT03305562 is a clinical study titled "Pediatric Hypertension Registry (PHREG)". Pediatric hypertension is increasingly common and is a precursor for adult cardiovascular and renal disease. But even during childhood, hypertension is associated with significant morbidity, including cognitive impairment and organ damage. However, the cause of pediatric hypertension, the response t...
What is the current status of trial NCT03305562?
This trial is currently terminated. The enrollment target is 179 participants. The study started on 2017-09-20. Estimated completion is 2021-06-22.
Who is sponsoring clinical trial NCT03305562?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06581198 · 179 participants · Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
- NCT07356323 · 179 participants · NA
A Prospective, Single-arm, Trial to Determine Contamination Rates When Using an Antibacterial Incise Drape During Orthopedic Surgery
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI